Authorized purpose: VBrain assists trained professionals in radiation-treatment planning by generating initial contours of known or diagnosed adult brain metastases, meningiomas, or acoustic neuromas and organs at risk from axial T1 contrast-enhanced brain MRI; contours must be finalized on an external DICOM-RT platform.
Clinical role
Retrieves brain MR images, applies tumor and organ-at-risk contouring and registration algorithms, and returns editable DICOM-RT structures for professional review.
Images and patients
MRI · Brain
Key limitation
Keep in mind: Adults and known or diagnosed brain metastases, meningiomas, or acoustic neuromas only; other tumor types and body parts are outside the labeled scope, the system is not for diagnosis, and every contour must be reviewed, modified, and confirmed on the external treatment-planning platform.
Clinical detailsPurpose, workflow fit, evidence, and safety record
Workflow navigation pilot
Workflow role has not yet been reviewed for this navigation pilot.
A tag identifies a documented role; it does not establish compatibility or local acceptance. Methods and sources
What does this software do?Authorized purpose: VBrain assists trained professionals in radiation-treatment planning by generating initial contours of known or diagnosed adult brain metastases, meningiomas, or acoustic neuromas and organs at risk from axial T1 contrast-enhanced brain MRI; contours must be finalized on an external DICOM-RT platform.
Which images or clinical context are in scope?Modality: MRI Anatomy or clinical context: Brain Input: Adult axial T1 contrast-enhanced brain MRI from PACS, with known or diagnosed tumors in the labeled categories and supported MR/CT registration data.
Who uses it?Intended users: Radiation oncologists, radiation planners, dosimetrists, and other trained professionals involved in brain radiation-treatment planning.
What does the software produce?Output: Initial tumor and organ-at-risk contours and rigidly registered MR/CT structures in DICOM-RT RTSTRUCT format.
What is its most important limitation?Key limitation: Adults and known or diagnosed brain metastases, meningiomas, or acoustic neuromas only; other tumor types and body parts are outside the labeled scope, the system is not for diagnosis, and every contour must be reviewed, modified, and confirmed on the external treatment-planning platform.
Clinical takeaway. Clinical role: VBrain assists trained professionals in radiation-treatment planning by generating initial contours of known or diagnosed adult brain metastases, meningiomas, or acoustic neuromas and organs at risk from axial T1 contrast-enhanced brain MRI; contours must be finalized on an external DICOM-RT platform.
Evidence takeaway. Evidence from the reviewed source record: The exact FDA document reports software regression testing to verify and validate the changes of VBrain, for a device of Major Level of Concern related to radiation therapy treatment planning, using verification and validation protocols, methods and acceptance criteria unchanged from the predicate submission. VBrain passed all V&V testing, and performance requirements and specifications were met. Results are as reported in the FDA submission, not independent validation.
Evidence context
Evidence context not reviewed for this FDA record.
Public-label constraints
Label constraints have not been reviewed for this exact FDA record. Unknown is not all ages or evidence of unsuitability.
Public-label constraints, not patient-level eligibility or a medical recommendation. Training and evaluation populations are separate. Read the original labeling and confirm the exact release and protocol.
Purpose
VBrain assists trained professionals in radiation-treatment planning by generating initial contours of known or diagnosed adult brain metastases, meningiomas, or acoustic neuromas and organs at risk from axial T1 contrast-enhanced brain MRI; contours must be finalized on an external DICOM-RT platform.
Retrieves brain MR images, applies tumor and organ-at-risk contouring and registration algorithms, and returns editable DICOM-RT structures for professional review.
Adults and known or diagnosed brain metastases, meningiomas, or acoustic neuromas only; other tumor types and body parts are outside the labeled scope, the system is not for diagnosis, and every contour must be reviewed, modified, and confirmed on the external treatment-planning platform.
The exact FDA document reports software regression testing to verify and validate the changes of VBrain, for a device of Major Level of Concern related to radiation therapy treatment planning, using verification and validation protocols, methods and acceptance criteria unchanged from the predicate submission. VBrain passed all V&V testing, and performance requirements and specifications were met. Results are as reported in the FDA submission, not independent validation.
Exact FDA submission
Checked 2026-11-14
Packet wording: "Regression testing was performed to verify and validate the changes of VBrain in accordance with" … "for software devices identified as Major Level of Concern related to radiation therapy treatment planning.". Read from the exact FDA decision document on 2026-11-14.
Metrics are shown only when they are tied to a source, endpoint, population, and tested product version. Candidate literature without exact product and version linkage is not shown as product evidence.
Evidence summary
The exact FDA document reports software regression testing to verify and validate the changes of VBrain, for a device of Major Level of Concern related to radiation therapy treatment planning, using verification and validation protocols, methods and acceptance criteria unchanged from the predicate submission. VBrain passed all V&V testing, and performance requirements and specifications were met. Results are as reported in the FDA submission, not independent validation.
FDA source
Exact FDA submission
Checked 2026-11-14
Packet wording: "Regression testing was performed to verify and validate the changes of VBrain in accordance with" … "for software devices identified as Major Level of Concern related to radiation therapy treatment planning.". Read from the exact FDA decision document on 2026-11-14.
Sensitivity is not promoted as a product-wide endpoint. Compare only an exact endpoint, threshold, population, version, and source if later verified.
Reported specificity
Not applicable
Not applicable
Not applicable
Checked 2026-09-04
Specificity is not promoted as a product-wide endpoint. Compare only an exact endpoint, threshold, population, version, and source if later verified.
No contextualized exact-version metric has completed evidence review. Regulatory-document values, when available, are shown above with their limitations.
K213628 FDA evidence package for VBrain
DesignFDA 510(k) software regression verification and validation for tumor, organ-at-risk, registration, and DICOM-RT functions.
PopulationSupported adult brain MRI and DICOM-RT treatment-planning workflows for the labeled tumor categories.
Scopeexact submission
Tested versionVBrain configuration described in K213628
IndependenceSponsor or vendor study
K213628
All listed tests passed in the FDA summary; manual finalization and external-platform review remain required.
Recall and adverse-event records are shown only after product matching. Adverse-event reports do not establish incidence or causality.
Postmarket safety review
The 2026-09-02 openFDA device-recall snapshot contained no record matched to K213628 by exact native submission identifier. This does not exclude product-family, later-version, or adverse-event information.
Public source
Exact FDA submission
Checked 2026-09-04
Exact-identifier review does not prove absence of all product-family safety signals.
No separate named-product Medicare payment was identified in the reviewed CMS coverage material. Evaluate the product within the applicable imaging or clinical service line and verify payer, site-of-service, coding, and coverage assumptions independently.
IT implementationDeployment, interfaces, data handling, and support
System and version relationships
Match the AI release, system build, configuration and region. Source documentation does not establish acceptance of an installed system.
No specific system/version pairing has completed review for this FDA record. A broad DICOM or product-family statement does not establish a named viewer build's support.
Public source context, not tested interoperability. Each hop needs its own release/configuration evidence. Missing or unavailable routes are not documented incompatibility. All local tests are planned, not passed; no installed-system acceptance is recorded.
Acquisition/source → routing → AI processing → returned objects → viewer/worklist/report → support owner
No specific route context has been source-reviewed for this record. Obtain both endpoint builds and documents; this is not a finding of incompatibility.
Acquisition/source
Source context, not route validation: Adult axial T1 contrast-enhanced brain MRI from PACS, with known or diagnosed tumors in the labeled categories and supported MR/CT registration data.
Scope: Exact FDA submission.
Confirm scanner/model, protocol, series completeness and both software builds.
Source context, not route validation: The FDA material describes PACS retrieval and return of DICOM data, rigid MR/CT registration, and export of editable DICOM-RT RTSTRUCT to an external treatment-planning platform.
Scope: Exact FDA submission. This is the interface boundary described in the exact FDA decision material; current local compatibility, routing, identity, archive, and downtime behavior still require acceptance testing.
Name gateways, destinations, transfer rules and failure visibility; a DICOM statement does not prove a route.
Source context, not route validation: The FDA material describes a PACS-connected radiation-planning workflow with an external DICOM-RT platform; current server placement, hosting, security, retention, availability, and site configuration remain unverified.
Scope: Exact FDA submission. This is the release-level boundary described in the exact FDA decision material; current hosting, contracts, security, availability, upgrade path, and site configuration remain separate evidence.
Confirm processing location, queue ownership, exclusions and exact AI build.
Unresolved route: Initial tumor and organ-at-risk contours and rigidly registered MR/CT structures in DICOM-RT RTSTRUCT format.
Scope: Exact FDA submission.
Confirm the named viewer/worklist/report build, display behavior and report transfer. Output support alone does not establish this endpoint. The displayed source describes output, not validated end-to-end delivery.
Unresolved route: Not established for the exact route.
Scope: Scope not established.
Name the local, platform and AI supplier support owners and escalation path.
Planned local route tests
No tests below have been performed or accepted.
Patient/study identity (planned). Use approved non-patient test data to verify identifiers, accession and result-to-study linkage at every hop.
Study completeness (planned). Test missing views/series, partial transfer, late arrivals, priors and unsupported acquisition inputs; confirm explicit refusal or fallback.
Ordering and duplicates (planned). Send out-of-order, repeated and corrected studies; verify worklist order, deduplication and no misleading stale results.
Report transfer (planned). Verify output object types, annotations, units, report content, destination and availability of original images.
Access (planned). Verify authorized roles, audit trail, denied access and support ownership at each destination.
Latency and failures (planned). Agree a workload and turnaround target; test queues, timeouts, missing results and fallback reading.
Updates and rollback (planned). Define version change control, revalidation triggers, stop-use criteria and a tested rollback route.
Local implementation checklist
Agree the evidence and acceptance owner with your team and suppliers. Checkmarks apply to this page only and are not acceptance receipts.
The FDA material describes a PACS-connected radiation-planning workflow with an external DICOM-RT platform; current server placement, hosting, security, retention, availability, and site configuration remain unverified.
Exact FDA submission
Checked 2026-09-04
This is the release-level boundary described in the exact FDA decision material; current hosting, contracts, security, availability, upgrade path, and site configuration remain separate evidence.
The FDA material describes PACS retrieval and return of DICOM data, rigid MR/CT registration, and export of editable DICOM-RT RTSTRUCT to an external treatment-planning platform.
Exact FDA submission
Checked 2026-09-04
This is the interface boundary described in the exact FDA decision material; current local compatibility, routing, identity, archive, and downtime behavior still require acceptance testing.
Only Radiation oncologists, radiation planners, dosimetrists, and other trained professionals involved in brain radiation-treatment planning should operate or interpret the product; local onboarding must cover the exact release, supported population, limitations, failure examples, escalation, downtime, and competency documentation.
Monitor K213628 by exact hardware, software, model, algorithm version, patient population, anatomy, protocol, operator, input quality, output edits or overrides, failed studies, repeat acquisition or rework, downstream impact, downtime, incidents, recalls, and updates. Track these product-specific limits: Adults and known or diagnosed brain metastases, meningiomas, or acoustic neuromas only; other tumor types and body parts are outside the labeled scope, the system is not for diagnosis, and every contour must be reviewed, modified, and confirmed on the external treatment-planning platform.
Exact FDA submission
Checked 2026-09-04
Buyer-facing monitoring guidance derived from the exact cleared scope; it is not a claim that the FDA package provides a live monitoring service.
The FDA material describes a PACS-connected radiation-planning workflow with an external DICOM-RT platform; current server placement, hosting, security, retention, availability, and site configuration remain unverified.
exact submission · checked 2026-09-04
FDA-described deployment boundaries do not establish current hosting contracts, security controls, uptime, or local qualification.
The FDA material describes PACS retrieval and return of DICOM data, rigid MR/CT registration, and export of editable DICOM-RT RTSTRUCT to an external treatment-planning platform.
exact submission · checked 2026-09-04
Test representative identifiers, orientation, geometry, measurements, units, routing, failure handling, and round trips locally.
Use a signed local test set for the supported population and workflow. Include common and difficult cases, exclusions, acquisition variation, failed or low-quality inputs, reviewer overrides, and downstream effects. Adults and known or diagnosed brain metastases, meningiomas, or acoustic neuromas only; other tumor types and body parts are outside the labeled scope, the system is not for diagnosis, and every contour must be reviewed, modified, and confirmed on the external treatment-planning platform.
exact submission · checked 2026-09-04
Define stop-use, escalation, rollback, and revalidation triggers before production use.
Model capital and recurring cost against net staff time after review, throughput, repeat imaging or rework, room time, consumables, infrastructure, training, service, downtime, upgrade, and replacement costs.
product family · checked 2026-09-04
No exact-product price was found in the reviewed public material; productivity or value claims require local evidence.
Sources & review detailsFDA identity, research record, source ledger, and history
Regulatory identity
FDA record and catalog context
The FDA listing establishes the regulatory identity. It does not by itself establish local workflow fit, pricing, security, or performance in your environment.
This audit distinguishes completed source review from fields that have not yet been researched.
Human reviewedStatus
2026-09-04Last searched
32Fields reviewed
11Source classes checked
7Screened PubMed leads
0Screened trial leads
0Unreviewed FDA recall leads
Screened seven PubMed records. PMID 37016416 identifies VBrain by Vysioneer but does not identify the tested software version or K213628; the other six are alias collisions. All seven were quarantined and none was promoted. The current discovery snapshot contains 7 PubMed and 0 ClinicalTrials.gov candidate records; its dated, count-matched human screening remains current. Unlinked candidates remain quarantined. Native FDA recall identifiers produced 0 postmarket candidate records; 0 have been reviewed (0 published, 0 rejected) and 0 remain unreviewed.
Candidate leads were screened against the exact product and tested version. Unlinked records remain quarantined.
Source classes: fda ai list, fda decision summary, acr ai central product, fda decision material, peer reviewed literature, clinical trial registry, reimbursement policy, fda device recall, pubmed, clinical trials, openfda device recall
Field review details
Recorded state, verification date, notes and sources for fields without a publishable value. Conflicting records stay explicitly unsettled here; no plain settled value is shown for them.
Public pricing: Not publicly available - checked 2026-09-04 - Exact FDA submission
No public list price for the exact cleared configuration was found. Obtain a written quote separating hardware or license basis, implementation, interfaces, infrastructure, training, service, upgrades, renewal, consumables, and exit costs.
Pricing model: Not yet reviewed
Setup and integration fees: Not yet reviewed
Recurring fees: Not yet reviewed
Minimum commitment: Not yet reviewed
Contract duration: Not yet reviewed
Renewal terms: Not yet reviewed
Cancellation terms: Not yet reviewed
Support and service terms: Not yet reviewed
Trial or pilot terms: Not yet reviewed
Data hosting location: Not yet reviewed
Data retention: Not yet reviewed
Documented data use: Not yet reviewed
Hardware requirements: Not yet reviewed
Network requirements: Not yet reviewed
Identity and access: Not yet reviewed
Security: Not publicly available - checked 2026-09-04 - Exact FDA submission
Public materials reviewed for this exact release do not establish the complete security posture. Request data-flow, identity, audit, encryption, retention, remote-access, vulnerability-management, backup, and incident-response evidence.
Authorized purpose: ANDI 2.2 processes brain MR images for atlas-assisted visualization, segmentation and volumetric quantification, presenting adjunctive DICOM-readable information for trained medical professionals; it does not predict, diagnose or interpret brain health.
Authorized purpose: Morph automatically labels, visualizes, and volumetrically quantifies segmentable brain structures from MR images and may compare measurements with reference percentile data; it is adjunctive and not the sole basis for final decisions.
Authorized purpose: Brain MRI morphometry and white matter hyperintensity quantification, including normative comparison and longitudinal change assessment for clinician review.
Authorized purpose: Swoop Portable MR Imaging System provides ultra-low-field point-of-care head MRI for all ages and includes deep-learning T1, T2, FLAIR, and DWI reconstruction.
Copy this public context and add the field, proposed wording and original source before sending. Nothing here is submitted automatically. Form-specific prefill has not been verified.
Permission to display a submission is not evidence verification. A submission enters editorial review; it does not approve a public change. Form availability, data entry, receipt, review and publication are separate steps. Data entry and receipt remain unverified.
Accepted repository change history
No entry has been added to this scoped change history for this record. This is not proof that the record never changed.